Patients with rheumatoid arthritis (RA) who used GLP-1 receptor agonists had less disease activity and improved ...

Beyond GLP-1 RA prescriptions, chronic kidney disease (CKD) patients require comprehensive care from doctors, dietitians, & ...

Lung cancer patients who take medications called GLP-1 receptor agonists—commonly prescribed for weight loss and diabetes ...

GLP-1 receptor agonists vs other second-line therapies were not associated with an increased thyroid cancer risk among patients with type 2 diabetes.

"Several preclinical and translational data studies suggest potential causative effects on bone health. One study with GLP-1 ...

Significantly lower risks seen for endometrial cancer, ovarian cancer, meningioma; nonsignificantly increased risk seen for kidney cancer.

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduction in the risk for developing uveitis, according to a study.

Patients with heart failure using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG) emissions per patient per year.

Women taking popular weight-loss medications during their reproductive years may be unaware of associated risks to pregnancy ...

Observational data indicate that GLP-1 receptor agonists might be beneficial for kidney transplant recipients with diabetes. GLP-1 receptor agonists are associated with better kidney graft and ...

Patients who are overweight or obese may have a lower risk of developing cancer if they take GLP-1 receptor agonists, data suggest.

A study reveals rising GLP-1 prescriptions in young women, highlighting low contraception use and potential risks for ...